ENDO USA, Inc. recalls
5 notices naming ENDO USA, Inc. as the recalling firm, since January 15, 2025. A notice covers specific products and lots, not every product of the firm.
Hazard and remedy text is quoted from the agency, unedited. The tag names the kind of risk with a word from that text. Every notice links to its official page.
ENDO USA, Inc.: Buprenorphine Hydrochloride
Hazard (FDA): Crystallization; identified as Buprenorphine free base
FDAMedicines
Endo USA, Inc.: Everolimus tablets 5mg and 3 more
Hazard (FDA): Failed Impurities/Degradation Specifications: Out of specification for impurity IP-C.
FDAMedicines
Endo USA, Inc.: Everolimus tablets 5mg
Hazard (FDA): Failed Impurities/Degradation Specifications: Out of specification for impurity IP-C.
FDAMedicines
ENDO USA, Inc.: Adrenalin Chloride Solution
Hazard (FDA): Labeling: Not Elsewhere Classified: misleading label similar in appearance to the FDA-approved drug product Adrenalin¿ (epinephrine injection, USP)
FDAMedicines
Endo USA, Inc.: Clonazepam Orally Disintegrating Tablet and 3 more
Hazard (FDA): Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled. The blister strips inside the product carton reflect the correct strength.
FDAMedicines